|Manufacturer:||Novo Nordisk manufactures Estrofem.|
|Uses:||The uses of Estrofem include:|
EstrofemŽ was especially developed and indicated for the treatment of oestrogen deficiency symptoms in women without a uterus, with effective symptom relief and good tolerability (continuous therapy with calendar pack of 28 tablets containing 1mg 17b-oestradiol). As there is no increased risk of developing cancer of the uterus lining in women without a uterus, they need not to take an additional progestogen. The drug is available in different dosages because a standardised unique dose is not optimal for every woman. Studies have demonstrated that after four weeks of treatment there is a significant reduction in hot flushes and other menopausal complaints. The administration of EstrofemŽ results in a significant increase of bone density.
EstrofemŽ is an oestrogen only treatment for effective symptom relief and one of the options for osteoporosis prevention in hysterectomised women.
Promotes growth and development of female reproductive system and secondary sex characteristics; affects release of pituitary gonadotropins; inhibits ovulation and prevents postpartum breast engorgement; conserves calcium and phosphorous and encourages bone formation; overrides stimulatory effects of testosterone.